NCT07241117 CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
| NCT ID | NCT07241117 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Washington University School of Medicine |
| Condition | Moderate to Severe Asthma |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-01-06 |
| Primary Completion | 2027-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 2,000 participants in total. It began in 2026-01-06 with a primary completion date of 2027-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Purpose: This study aims to improve asthma care by helping clinicians at community health centers prescribe a guideline-recommended treatment called SMART (Single Maintenance and Reliever Therapy). The investigators will provide training and resources to clinicians, give feedback on prescribing patterns, and offer educational tools for patients and providers. The investigators will roll out these resources in stages across clinics. The study will measure how well the program helps clinicians prescribe SMART therapy and whether it reduces asthma exacerbations in patients.
Eligibility Criteria
The study population can be viewed from the cluster (clinic), clinician, staff, or patient level. At the cluster (clinic) level: To be eligible to participate in this study, a cluster (clinic) must meet all the following criteria: 1. Active participation in the St. Louis Integrated Health Center Network for Community Academic Partnerships. 2. Employment of at least 3 clinicians who commonly manage adult asthma (defined as managing asthma for at least one adult asthma patient, on average, on a weekly basis). 3. Data provided to Azara for data queries, and 4. Willing and able to receive all components of the SMART implementation bundle (i.e., initial educational outreach visit, ongoing practice facilitation/supervision, audit \& feedback, and provision of education of patient-level education aides and SMART asthma action plans and monthly operations committee meetings). At the clinician/clinical staff level: To be eligible to participate in this study, a clinician/clinical staff member must meet all of the following criteria: 1. Provision of a signed and dated informed consent form. 2. Current state licenses of physician, assistant physician, nurse practitioner, or physician assistant. 3. Regularly cares for adults with asthma (which may include those trained in family medicine, internal medicine, obstetrics/gynecology, and/or specialty medicine). 4. Willing and able to integrate the SMART implementation bundle into their practice. 5. Willing and able to participate for the entire duration of the study, including the pre-implementation, active implementation, and post-implementation periods. 6. Willing to provide data on prescribing patterns and asthma patient outcomes for the duration of the study. At the patient level: To be eligible to participate in this study, a patient must meet all of the following criteria: 1. Age ≥12 years old 2. Diagnosis of asthma, of any severity, coded (i.e., International Classification of Diseases \[ICD\]-10-CM: J45\*\*). 3. The patient has had ≥2 asthma exacerbations in the last year during which systemic corticosteroids were prescribed, and/or the encounter contains an active prescription for an inhaler that is congruent with medium-dose (or higher) maintenance inhaled corticosteroids (ICS) inhalers or low-dose (or higher) ICS-long-acting β-agonist (LABA) inhalers with concomitant reliever short-acting β-agonist inhalers.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07241117 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Moderate to Severe Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07241117 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07241117 currently recruiting?
Yes, NCT07241117 is actively recruiting participants. Contact the research team at kringsj@wustl.edu for enrollment information.
Where is the NCT07241117 trial being conducted?
This trial is being conducted at St Louis, United States, St Louis, United States, St Louis, United States, St Louis, United States and 3 additional locations.
Who is sponsoring the NCT07241117 clinical trial?
NCT07241117 is sponsored by Washington University School of Medicine. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.